nodes	percent_of_prediction	percent_of_DWPC	metapath
Bismuth Subsalicylate—PTGS2—urinary bladder cancer	0.464	1	CbGaD
Bismuth Subsalicylate—PTGS2—Cisplatin—urinary bladder cancer	0.0712	0.252	CbGbCtD
Bismuth Subsalicylate—PTGS2—Etoposide—urinary bladder cancer	0.07	0.248	CbGbCtD
Bismuth Subsalicylate—PTGS1—Etoposide—urinary bladder cancer	0.0591	0.209	CbGbCtD
Bismuth Subsalicylate—ALB—Fluorouracil—urinary bladder cancer	0.0529	0.187	CbGbCtD
Bismuth Subsalicylate—ALB—Methotrexate—urinary bladder cancer	0.0291	0.103	CbGbCtD
Bismuth Subsalicylate—TF—urine—urinary bladder cancer	0.0149	0.278	CbGeAlD
Bismuth Subsalicylate—TF—prostate gland—urinary bladder cancer	0.00536	0.0999	CbGeAlD
Bismuth Subsalicylate—TF—epithelium—urinary bladder cancer	0.00394	0.0734	CbGeAlD
Bismuth Subsalicylate—TF—renal system—urinary bladder cancer	0.00366	0.0681	CbGeAlD
Bismuth Subsalicylate—TF—female reproductive system—urinary bladder cancer	0.00293	0.0545	CbGeAlD
Bismuth Subsalicylate—TF—vagina—urinary bladder cancer	0.00265	0.0493	CbGeAlD
Bismuth Subsalicylate—TF—lymph node—urinary bladder cancer	0.00171	0.0319	CbGeAlD
Bismuth Subsalicylate—PTGS1—prostate gland—urinary bladder cancer	0.00159	0.0296	CbGeAlD
Bismuth Subsalicylate—PTGS2—prostate gland—urinary bladder cancer	0.00152	0.0283	CbGeAlD
Bismuth Subsalicylate—PTGS1—seminal vesicle—urinary bladder cancer	0.00135	0.0251	CbGeAlD
Bismuth Subsalicylate—PTGS2—seminal vesicle—urinary bladder cancer	0.00129	0.024	CbGeAlD
Bismuth Subsalicylate—PTGS1—epithelium—urinary bladder cancer	0.00117	0.0218	CbGeAlD
Bismuth Subsalicylate—PTGS1—smooth muscle tissue—urinary bladder cancer	0.00113	0.021	CbGeAlD
Bismuth Subsalicylate—PTGS2—epithelium—urinary bladder cancer	0.00112	0.0208	CbGeAlD
Bismuth Subsalicylate—PTGS1—renal system—urinary bladder cancer	0.00108	0.0202	CbGeAlD
Bismuth Subsalicylate—PTGS2—smooth muscle tissue—urinary bladder cancer	0.00108	0.02	CbGeAlD
Bismuth Subsalicylate—PTGS2—renal system—urinary bladder cancer	0.00104	0.0193	CbGeAlD
Bismuth Subsalicylate—PTGS2—urethra—urinary bladder cancer	0.00102	0.019	CbGeAlD
Bismuth Subsalicylate—Skin exfoliation—Gemcitabine—urinary bladder cancer	0.000933	0.00676	CcSEcCtD
Bismuth Subsalicylate—ALB—lymph node—urinary bladder cancer	0.000891	0.0166	CbGeAlD
Bismuth Subsalicylate—Oesophagitis—Fluorouracil—urinary bladder cancer	0.000878	0.00636	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Carboplatin—urinary bladder cancer	0.000876	0.00635	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Cisplatin—urinary bladder cancer	0.00087	0.0063	CcSEcCtD
Bismuth Subsalicylate—PTGS1—female reproductive system—urinary bladder cancer	0.000868	0.0162	CbGeAlD
Bismuth Subsalicylate—Venous thrombosis—Epirubicin—urinary bladder cancer	0.000867	0.00628	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Valrubicin—urinary bladder cancer	0.000847	0.00613	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Mitomycin—urinary bladder cancer	0.000831	0.00602	CcSEcCtD
Bismuth Subsalicylate—PTGS2—female reproductive system—urinary bladder cancer	0.00083	0.0155	CbGeAlD
Bismuth Subsalicylate—Oedema—Mitomycin—urinary bladder cancer	0.000824	0.00597	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Valrubicin—urinary bladder cancer	0.000819	0.00593	CcSEcCtD
Bismuth Subsalicylate—Gastric ulcer—Epirubicin—urinary bladder cancer	0.000805	0.00583	CcSEcCtD
Bismuth Subsalicylate—Venous thrombosis—Doxorubicin—urinary bladder cancer	0.000802	0.00581	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Etoposide—urinary bladder cancer	0.000797	0.00577	CcSEcCtD
Bismuth Subsalicylate—Deafness—Gemcitabine—urinary bladder cancer	0.000793	0.00575	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Valrubicin—urinary bladder cancer	0.000791	0.00573	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Mitomycin—urinary bladder cancer	0.000786	0.00569	CcSEcCtD
Bismuth Subsalicylate—PTGS1—vagina—urinary bladder cancer	0.000785	0.0146	CbGeAlD
Bismuth Subsalicylate—Phlebitis—Cisplatin—urinary bladder cancer	0.000768	0.00556	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Etoposide—urinary bladder cancer	0.000763	0.00552	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Valrubicin—urinary bladder cancer	0.000761	0.00551	CcSEcCtD
Bismuth Subsalicylate—Rash—Valrubicin—urinary bladder cancer	0.000755	0.00546	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Valrubicin—urinary bladder cancer	0.000754	0.00546	CcSEcCtD
Bismuth Subsalicylate—PTGS2—vagina—urinary bladder cancer	0.000751	0.014	CbGeAlD
Bismuth Subsalicylate—Headache—Valrubicin—urinary bladder cancer	0.00075	0.00543	CcSEcCtD
Bismuth Subsalicylate—Gastric ulcer—Doxorubicin—urinary bladder cancer	0.000745	0.0054	CcSEcCtD
Bismuth Subsalicylate—Deafness—Cisplatin—urinary bladder cancer	0.000739	0.00535	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Mitomycin—urinary bladder cancer	0.000733	0.00531	CcSEcCtD
Bismuth Subsalicylate—Burning sensation—Methotrexate—urinary bladder cancer	0.00072	0.00521	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Mitomycin—urinary bladder cancer	0.000717	0.00519	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Fluorouracil—urinary bladder cancer	0.000712	0.00516	CcSEcCtD
Bismuth Subsalicylate—Nausea—Valrubicin—urinary bladder cancer	0.000711	0.00515	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Methotrexate—urinary bladder cancer	0.000706	0.00512	CcSEcCtD
Bismuth Subsalicylate—Pain—Mitomycin—urinary bladder cancer	0.000705	0.00511	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Etoposide—urinary bladder cancer	0.000703	0.00509	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Mitomycin—urinary bladder cancer	0.000679	0.00492	CcSEcCtD
Bismuth Subsalicylate—Burning sensation—Epirubicin—urinary bladder cancer	0.000674	0.00488	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Cisplatin—urinary bladder cancer	0.000664	0.00481	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Thiotepa—urinary bladder cancer	0.000664	0.00481	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Epirubicin—urinary bladder cancer	0.000661	0.00479	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Mitomycin—urinary bladder cancer	0.000652	0.00472	CcSEcCtD
Bismuth Subsalicylate—Burning sensation—Doxorubicin—urinary bladder cancer	0.000623	0.00451	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Thiotepa—urinary bladder cancer	0.000613	0.00444	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Doxorubicin—urinary bladder cancer	0.000612	0.00443	CcSEcCtD
Bismuth Subsalicylate—Hallucination—Thiotepa—urinary bladder cancer	0.000581	0.00421	CcSEcCtD
Bismuth Subsalicylate—Stinging—Epirubicin—urinary bladder cancer	0.000578	0.00418	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Methotrexate—urinary bladder cancer	0.000573	0.00415	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Mitomycin—urinary bladder cancer	0.000564	0.00409	CcSEcCtD
Bismuth Subsalicylate—Abdominal discomfort—Cisplatin—urinary bladder cancer	0.000548	0.00397	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Mitomycin—urinary bladder cancer	0.000545	0.00395	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Thiotepa—urinary bladder cancer	0.000544	0.00394	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Epirubicin—urinary bladder cancer	0.000536	0.00388	CcSEcCtD
Bismuth Subsalicylate—Stinging—Doxorubicin—urinary bladder cancer	0.000534	0.00387	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Mitomycin—urinary bladder cancer	0.000524	0.0038	CcSEcCtD
Bismuth Subsalicylate—Rash—Mitomycin—urinary bladder cancer	0.00052	0.00376	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Mitomycin—urinary bladder cancer	0.000519	0.00376	CcSEcCtD
Bismuth Subsalicylate—Headache—Mitomycin—urinary bladder cancer	0.000516	0.00374	CcSEcCtD
Bismuth Subsalicylate—Erythema—Thiotepa—urinary bladder cancer	0.000508	0.00368	CcSEcCtD
Bismuth Subsalicylate—PTGS1—lymph node—urinary bladder cancer	0.000508	0.00946	CbGeAlD
Bismuth Subsalicylate—Epistaxis—Fluorouracil—urinary bladder cancer	0.000507	0.00367	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Doxorubicin—urinary bladder cancer	0.000496	0.00359	CcSEcCtD
Bismuth Subsalicylate—Nausea—Mitomycin—urinary bladder cancer	0.00049	0.00355	CcSEcCtD
Bismuth Subsalicylate—PTGS2—lymph node—urinary bladder cancer	0.000486	0.00904	CbGeAlD
Bismuth Subsalicylate—Skin exfoliation—Methotrexate—urinary bladder cancer	0.000477	0.00346	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.000464	0.00336	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Methotrexate—urinary bladder cancer	0.000452	0.00327	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Epirubicin—urinary bladder cancer	0.000447	0.00324	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Epirubicin—urinary bladder cancer	0.000428	0.0031	CcSEcCtD
Bismuth Subsalicylate—Erythema—Gemcitabine—urinary bladder cancer	0.000427	0.0031	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Cisplatin—urinary bladder cancer	0.000427	0.00309	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Epirubicin—urinary bladder cancer	0.000423	0.00306	CcSEcCtD
Bismuth Subsalicylate—Erythema—Fluorouracil—urinary bladder cancer	0.00042	0.00304	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Thiotepa—urinary bladder cancer	0.000418	0.00303	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Doxorubicin—urinary bladder cancer	0.000413	0.00299	CcSEcCtD
Bismuth Subsalicylate—Infection—Thiotepa—urinary bladder cancer	0.000412	0.00298	CcSEcCtD
Bismuth Subsalicylate—Erythema—Cisplatin—urinary bladder cancer	0.000398	0.00288	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Etoposide—urinary bladder cancer	0.000396	0.00287	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Doxorubicin—urinary bladder cancer	0.000396	0.00287	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Thiotepa—urinary bladder cancer	0.000395	0.00286	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Epirubicin—urinary bladder cancer	0.000394	0.00286	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Doxorubicin—urinary bladder cancer	0.000391	0.00284	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Methotrexate—urinary bladder cancer	0.00037	0.00268	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Thiotepa—urinary bladder cancer	0.000369	0.00267	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Thiotepa—urinary bladder cancer	0.000365	0.00264	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Doxorubicin—urinary bladder cancer	0.000365	0.00264	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Thiotepa—urinary bladder cancer	0.00036	0.00261	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Etoposide—urinary bladder cancer	0.000357	0.00259	CcSEcCtD
Bismuth Subsalicylate—Constipation—Thiotepa—urinary bladder cancer	0.000355	0.00257	CcSEcCtD
Bismuth Subsalicylate—Pain—Thiotepa—urinary bladder cancer	0.000355	0.00257	CcSEcCtD
Bismuth Subsalicylate—Oedema—Gemcitabine—urinary bladder cancer	0.000349	0.00253	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Epirubicin—urinary bladder cancer	0.000347	0.00251	CcSEcCtD
Bismuth Subsalicylate—Infection—Gemcitabine—urinary bladder cancer	0.000346	0.00251	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Fluorouracil—urinary bladder cancer	0.000346	0.0025	CcSEcCtD
Bismuth Subsalicylate—Oedema—Fluorouracil—urinary bladder cancer	0.000343	0.00248	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000342	0.00247	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Epirubicin—urinary bladder cancer	0.000341	0.00247	CcSEcCtD
Bismuth Subsalicylate—Infection—Fluorouracil—urinary bladder cancer	0.000341	0.00247	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Gemcitabine—urinary bladder cancer	0.000332	0.00241	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Thiotepa—urinary bladder cancer	0.000329	0.00239	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Thiotepa—urinary bladder cancer	0.000328	0.00237	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Fluorouracil—urinary bladder cancer	0.000327	0.00237	CcSEcCtD
Bismuth Subsalicylate—Oedema—Cisplatin—urinary bladder cancer	0.000325	0.00235	CcSEcCtD
Bismuth Subsalicylate—Infection—Cisplatin—urinary bladder cancer	0.000323	0.00234	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Doxorubicin—urinary bladder cancer	0.000321	0.00232	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Doxorubicin—urinary bladder cancer	0.000316	0.00229	CcSEcCtD
Bismuth Subsalicylate—Asthma—Methotrexate—urinary bladder cancer	0.000314	0.00227	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.00031	0.00225	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Gemcitabine—urinary bladder cancer	0.00031	0.00225	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Cisplatin—urinary bladder cancer	0.00031	0.00224	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Fluorouracil—urinary bladder cancer	0.000305	0.00221	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000303	0.0022	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000302	0.00219	CcSEcCtD
Bismuth Subsalicylate—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000301	0.00218	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Etoposide—urinary bladder cancer	0.0003	0.00217	CcSEcCtD
Bismuth Subsalicylate—Constipation—Gemcitabine—urinary bladder cancer	0.000298	0.00216	CcSEcCtD
Bismuth Subsalicylate—Pain—Gemcitabine—urinary bladder cancer	0.000298	0.00216	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000298	0.00216	CcSEcCtD
Bismuth Subsalicylate—Infection—Etoposide—urinary bladder cancer	0.000296	0.00214	CcSEcCtD
Bismuth Subsalicylate—Asthma—Epirubicin—urinary bladder cancer	0.000294	0.00213	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Thiotepa—urinary bladder cancer	0.000293	0.00212	CcSEcCtD
Bismuth Subsalicylate—Pain—Fluorouracil—urinary bladder cancer	0.000293	0.00212	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000287	0.00208	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000287	0.00208	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Etoposide—urinary bladder cancer	0.000284	0.00206	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Thiotepa—urinary bladder cancer	0.000284	0.00205	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Cisplatin—urinary bladder cancer	0.000283	0.00205	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000283	0.00205	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Methotrexate—urinary bladder cancer	0.00028	0.00203	CcSEcCtD
Bismuth Subsalicylate—Pain—Cisplatin—urinary bladder cancer	0.000278	0.00201	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000276	0.002	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Thiotepa—urinary bladder cancer	0.000274	0.00199	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Fluorouracil—urinary bladder cancer	0.000272	0.00197	CcSEcCtD
Bismuth Subsalicylate—Asthma—Doxorubicin—urinary bladder cancer	0.000272	0.00197	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000271	0.00196	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000268	0.00194	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Epirubicin—urinary bladder cancer	0.000267	0.00193	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Etoposide—urinary bladder cancer	0.000265	0.00192	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Methotrexate—urinary bladder cancer	0.000264	0.00191	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Thiotepa—urinary bladder cancer	0.000264	0.00191	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Epirubicin—urinary bladder cancer	0.000262	0.0019	CcSEcCtD
Bismuth Subsalicylate—Rash—Thiotepa—urinary bladder cancer	0.000261	0.00189	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Thiotepa—urinary bladder cancer	0.000261	0.00189	CcSEcCtD
Bismuth Subsalicylate—Headache—Thiotepa—urinary bladder cancer	0.00026	0.00188	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Etoposide—urinary bladder cancer	0.000259	0.00188	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Cisplatin—urinary bladder cancer	0.000257	0.00186	CcSEcCtD
Bismuth Subsalicylate—Pain—Etoposide—urinary bladder cancer	0.000255	0.00184	CcSEcCtD
Bismuth Subsalicylate—Constipation—Etoposide—urinary bladder cancer	0.000255	0.00184	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Methotrexate—urinary bladder cancer	0.000251	0.00182	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Doxorubicin—urinary bladder cancer	0.000247	0.00179	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Epirubicin—urinary bladder cancer	0.000247	0.00179	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Gemcitabine—urinary bladder cancer	0.000247	0.00179	CcSEcCtD
Bismuth Subsalicylate—Nausea—Thiotepa—urinary bladder cancer	0.000246	0.00178	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Etoposide—urinary bladder cancer	0.000245	0.00178	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Fluorouracil—urinary bladder cancer	0.000243	0.00176	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Doxorubicin—urinary bladder cancer	0.000242	0.00175	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000239	0.00173	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000237	0.00172	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Etoposide—urinary bladder cancer	0.000237	0.00171	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Etoposide—urinary bladder cancer	0.000235	0.00171	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Epirubicin—urinary bladder cancer	0.000235	0.0017	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000235	0.0017	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Methotrexate—urinary bladder cancer	0.000234	0.0017	CcSEcCtD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—SOD2—urinary bladder cancer	0.00023	0.0037	CbGpPWpGaD
Bismuth Subsalicylate—Epistaxis—Doxorubicin—urinary bladder cancer	0.000228	0.00165	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—urinary bladder cancer	0.000227	0.00365	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Fluorouracil—urinary bladder cancer	0.000227	0.00164	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Cisplatin—urinary bladder cancer	0.000222	0.00161	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000222	0.00161	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Gemcitabine—urinary bladder cancer	0.000222	0.00161	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000221	0.00355	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Gemcitabine—urinary bladder cancer	0.00022	0.00159	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Gemcitabine—urinary bladder cancer	0.00022	0.00159	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Epirubicin—urinary bladder cancer	0.000219	0.00159	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Biological oxidations—HPGDS—urinary bladder cancer	0.000219	0.00351	CbGpPWpGaD
Bismuth Subsalicylate—Erythema—Methotrexate—urinary bladder cancer	0.000219	0.00158	CcSEcCtD
Bismuth Subsalicylate—Headache—Gemcitabine—urinary bladder cancer	0.000218	0.00158	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Fluorouracil—urinary bladder cancer	0.000218	0.00158	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Doxorubicin—urinary bladder cancer	0.000217	0.00157	CcSEcCtD
Bismuth Subsalicylate—Rash—Fluorouracil—urinary bladder cancer	0.000216	0.00157	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Fluorouracil—urinary bladder cancer	0.000216	0.00156	CcSEcCtD
Bismuth Subsalicylate—Headache—Fluorouracil—urinary bladder cancer	0.000215	0.00156	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Methotrexate—urinary bladder cancer	0.000214	0.00155	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Biological oxidations—GSTT1—urinary bladder cancer	0.000212	0.00341	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000211	0.0034	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Etoposide—urinary bladder cancer	0.000211	0.00153	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000209	0.00336	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Gemcitabine—urinary bladder cancer	0.000207	0.0015	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Cisplatin—urinary bladder cancer	0.000207	0.0015	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—urinary bladder cancer	0.000207	0.00332	CbGpPWpGaD
Bismuth Subsalicylate—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000206	0.00149	CcSEcCtD
Bismuth Subsalicylate—Rash—Cisplatin—urinary bladder cancer	0.000205	0.00148	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Cisplatin—urinary bladder cancer	0.000205	0.00148	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000205	0.00329	CbGpPWpGaD
Bismuth Subsalicylate—Erythema—Epirubicin—urinary bladder cancer	0.000205	0.00148	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000204	0.00328	CbGpPWpGaD
Bismuth Subsalicylate—Diarrhoea—Etoposide—urinary bladder cancer	0.000204	0.00148	CcSEcCtD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	0.000204	0.00327	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Fluorouracil—urinary bladder cancer	0.000204	0.00148	CcSEcCtD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—MTHFR—urinary bladder cancer	0.000203	0.00326	CbGpPWpGaD
Bismuth Subsalicylate—Tinnitus—Doxorubicin—urinary bladder cancer	0.000203	0.00147	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Epirubicin—urinary bladder cancer	0.0002	0.00145	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Etoposide—urinary bladder cancer	0.000197	0.00143	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000196	0.00315	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Cisplatin—urinary bladder cancer	0.000193	0.0014	CcSEcCtD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—NCOR1—urinary bladder cancer	0.00019	0.00306	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—GSTM1—urinary bladder cancer	0.00019	0.00306	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Etoposide—urinary bladder cancer	0.000189	0.00137	CcSEcCtD
Bismuth Subsalicylate—Erythema—Doxorubicin—urinary bladder cancer	0.000189	0.00137	CcSEcCtD
Bismuth Subsalicylate—Rash—Etoposide—urinary bladder cancer	0.000188	0.00136	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Etoposide—urinary bladder cancer	0.000188	0.00136	CcSEcCtD
Bismuth Subsalicylate—ALB—Folate Metabolism—SOD2—urinary bladder cancer	0.000187	0.00301	CbGpPWpGaD
Bismuth Subsalicylate—Headache—Etoposide—urinary bladder cancer	0.000187	0.00135	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000185	0.00134	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000184	0.00296	CbGpPWpGaD
Bismuth Subsalicylate—Confusional state—Methotrexate—urinary bladder cancer	0.00018	0.0013	CcSEcCtD
Bismuth Subsalicylate—ALB—Folate Metabolism—GPX1—urinary bladder cancer	0.000179	0.00287	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	0.000178	0.00286	CbGpPWpGaD
Bismuth Subsalicylate—Infection—Methotrexate—urinary bladder cancer	0.000177	0.00128	CcSEcCtD
Bismuth Subsalicylate—Nausea—Etoposide—urinary bladder cancer	0.000177	0.00128	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000176	0.00282	CbGpPWpGaD
Bismuth Subsalicylate—Anorexia—Methotrexate—urinary bladder cancer	0.00017	0.00123	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Epirubicin—urinary bladder cancer	0.000168	0.00122	CcSEcCtD
Bismuth Subsalicylate—TF—Hemostasis—PLAU—urinary bladder cancer	0.000168	0.00269	CbGpPWpGaD
Bismuth Subsalicylate—Oedema—Epirubicin—urinary bladder cancer	0.000167	0.00121	CcSEcCtD
Bismuth Subsalicylate—Infection—Epirubicin—urinary bladder cancer	0.000166	0.0012	CcSEcCtD
Bismuth Subsalicylate—ALB—Folate Metabolism—MTHFR—urinary bladder cancer	0.000165	0.00265	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	0.000164	0.00263	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000162	0.0026	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.00016	0.00257	CbGpPWpGaD
Bismuth Subsalicylate—Anorexia—Epirubicin—urinary bladder cancer	0.000159	0.00115	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000159	0.00255	CbGpPWpGaD
Bismuth Subsalicylate—Somnolence—Methotrexate—urinary bladder cancer	0.000159	0.00115	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000158	0.00254	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—urinary bladder cancer	0.000158	0.00253	CbGpPWpGaD
Bismuth Subsalicylate—Dyspepsia—Methotrexate—urinary bladder cancer	0.000157	0.00114	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Doxorubicin—urinary bladder cancer	0.000156	0.00113	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Methotrexate—urinary bladder cancer	0.000155	0.00112	CcSEcCtD
Bismuth Subsalicylate—Oedema—Doxorubicin—urinary bladder cancer	0.000154	0.00112	CcSEcCtD
Bismuth Subsalicylate—Infection—Doxorubicin—urinary bladder cancer	0.000153	0.00111	CcSEcCtD
Bismuth Subsalicylate—Pain—Methotrexate—urinary bladder cancer	0.000153	0.0011	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000152	0.00244	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—urinary bladder cancer	0.000151	0.00242	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000149	0.00239	CbGpPWpGaD
Bismuth Subsalicylate—Somnolence—Epirubicin—urinary bladder cancer	0.000148	0.00107	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Doxorubicin—urinary bladder cancer	0.000147	0.00107	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Biological oxidations—GSTP1—urinary bladder cancer	0.000147	0.00236	CbGpPWpGaD
Bismuth Subsalicylate—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000147	0.00106	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Epirubicin—urinary bladder cancer	0.000147	0.00106	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Epirubicin—urinary bladder cancer	0.000145	0.00105	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000144	0.00232	CbGpPWpGaD
Bismuth Subsalicylate—Constipation—Epirubicin—urinary bladder cancer	0.000143	0.00103	CcSEcCtD
Bismuth Subsalicylate—Pain—Epirubicin—urinary bladder cancer	0.000143	0.00103	CcSEcCtD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000142	0.00228	CbGpPWpGaD
Bismuth Subsalicylate—Urticaria—Methotrexate—urinary bladder cancer	0.000142	0.00103	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Methotrexate—urinary bladder cancer	0.000141	0.00102	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000141	0.00226	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—CREBBP—urinary bladder cancer	0.000138	0.00222	CbGpPWpGaD
Bismuth Subsalicylate—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000138	0.000996	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Doxorubicin—urinary bladder cancer	0.000137	0.000995	CcSEcCtD
Bismuth Subsalicylate—TF—Hemostasis—IGF1—urinary bladder cancer	0.000137	0.00219	CbGpPWpGaD
Bismuth Subsalicylate—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000136	0.000985	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Biological oxidations—GSTM1—urinary bladder cancer	0.000135	0.00217	CbGpPWpGaD
Bismuth Subsalicylate—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000134	0.000973	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Epirubicin—urinary bladder cancer	0.000133	0.000961	CcSEcCtD
Bismuth Subsalicylate—Pain—Doxorubicin—urinary bladder cancer	0.000132	0.000957	CcSEcCtD
Bismuth Subsalicylate—Constipation—Doxorubicin—urinary bladder cancer	0.000132	0.000957	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Epirubicin—urinary bladder cancer	0.000132	0.000956	CcSEcCtD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000131	0.00211	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CREBBP—urinary bladder cancer	0.000131	0.00211	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	0.00013	0.00209	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—urinary bladder cancer	0.000129	0.00207	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000128	0.00205	CbGpPWpGaD
Bismuth Subsalicylate—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000127	0.000922	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Methotrexate—urinary bladder cancer	0.000126	0.000914	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000126	0.00202	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000125	0.00201	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—RHOA—urinary bladder cancer	0.000125	0.00201	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000123	0.00198	CbGpPWpGaD
Bismuth Subsalicylate—Urticaria—Doxorubicin—urinary bladder cancer	0.000123	0.000889	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000122	0.000884	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Methotrexate—urinary bladder cancer	0.000122	0.000884	CcSEcCtD
Bismuth Subsalicylate—TF—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	0.00012	0.00192	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Epirubicin—urinary bladder cancer	0.000118	0.000855	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Methotrexate—urinary bladder cancer	0.000118	0.000854	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000117	0.00188	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000117	0.00188	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000116	0.00187	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	0.000115	0.00184	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CDK4—urinary bladder cancer	0.000114	0.00184	CbGpPWpGaD
Bismuth Subsalicylate—Diarrhoea—Epirubicin—urinary bladder cancer	0.000114	0.000827	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Methotrexate—urinary bladder cancer	0.000113	0.000821	CcSEcCtD
Bismuth Subsalicylate—Rash—Methotrexate—urinary bladder cancer	0.000112	0.000815	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Methotrexate—urinary bladder cancer	0.000112	0.000814	CcSEcCtD
Bismuth Subsalicylate—Headache—Methotrexate—urinary bladder cancer	0.000112	0.000809	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Epirubicin—urinary bladder cancer	0.00011	0.0008	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—urinary bladder cancer	0.00011	0.00176	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Doxorubicin—urinary bladder cancer	0.000109	0.000792	CcSEcCtD
Bismuth Subsalicylate—ALB—Platelet degranulation—IGF1—urinary bladder cancer	0.000109	0.00175	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Epirubicin—urinary bladder cancer	0.000106	0.000769	CcSEcCtD
Bismuth Subsalicylate—Nausea—Methotrexate—urinary bladder cancer	0.000106	0.000767	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000106	0.000765	CcSEcCtD
Bismuth Subsalicylate—Rash—Epirubicin—urinary bladder cancer	0.000105	0.000762	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Epirubicin—urinary bladder cancer	0.000105	0.000762	CcSEcCtD
Bismuth Subsalicylate—TF—Hemostasis—IL2—urinary bladder cancer	0.000105	0.00169	CbGpPWpGaD
Bismuth Subsalicylate—Headache—Epirubicin—urinary bladder cancer	0.000105	0.000757	CcSEcCtD
Bismuth Subsalicylate—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—urinary bladder cancer	0.000104	0.00167	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Doxorubicin—urinary bladder cancer	0.000102	0.00074	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000102	0.00163	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000101	0.00163	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	9.98e-05	0.0016	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—RB1—urinary bladder cancer	9.95e-05	0.0016	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Epirubicin—urinary bladder cancer	9.92e-05	0.000718	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	9.89e-05	0.00159	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Doxorubicin—urinary bladder cancer	9.82e-05	0.000711	CcSEcCtD
Bismuth Subsalicylate—ALB—Folate Metabolism—IL2—urinary bladder cancer	9.76e-05	0.00157	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Doxorubicin—urinary bladder cancer	9.74e-05	0.000705	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Doxorubicin—urinary bladder cancer	9.73e-05	0.000705	CcSEcCtD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CCND1—urinary bladder cancer	9.7e-05	0.00156	CbGpPWpGaD
Bismuth Subsalicylate—Headache—Doxorubicin—urinary bladder cancer	9.68e-05	0.000701	CcSEcCtD
Bismuth Subsalicylate—TF—Hemostasis—EP300—urinary bladder cancer	9.42e-05	0.00151	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	9.38e-05	0.00151	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Doxorubicin—urinary bladder cancer	9.18e-05	0.000665	CcSEcCtD
Bismuth Subsalicylate—TF—Hemostasis—SRC—urinary bladder cancer	9.16e-05	0.00147	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—RHOA—urinary bladder cancer	9.03e-05	0.00145	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GSTZ1—urinary bladder cancer	9.01e-05	0.00145	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—EP300—urinary bladder cancer	8.93e-05	0.00143	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	8.84e-05	0.00142	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—TNF—urinary bladder cancer	8.79e-05	0.00141	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—TNF—urinary bladder cancer	8.74e-05	0.0014	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GSTO2—urinary bladder cancer	8.54e-05	0.00137	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—NAT1—urinary bladder cancer	8.54e-05	0.00137	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	8.47e-05	0.00136	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	8.4e-05	0.00135	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	8.37e-05	0.00134	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—GSTO2—urinary bladder cancer	8.1e-05	0.0013	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CXCL8—urinary bladder cancer	7.93e-05	0.00127	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	7.82e-05	0.00126	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—UGT2B7—urinary bladder cancer	7.81e-05	0.00125	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	7.78e-05	0.00125	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—MYC—urinary bladder cancer	7.78e-05	0.00125	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	7.75e-05	0.00125	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—KRAS—urinary bladder cancer	7.59e-05	0.00122	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—IL2—urinary bladder cancer	7.58e-05	0.00122	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CCND1—urinary bladder cancer	7.39e-05	0.00119	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—KRAS—urinary bladder cancer	7.19e-05	0.00115	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—MMP9—urinary bladder cancer	7.17e-05	0.00115	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GSTZ1—urinary bladder cancer	7.15e-05	0.00115	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—TNF—urinary bladder cancer	7.11e-05	0.00114	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CYP4B1—urinary bladder cancer	7.03e-05	0.00113	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—TNF—urinary bladder cancer	6.98e-05	0.00112	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	6.9e-05	0.00111	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	6.79e-05	0.00109	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GSTO2—urinary bladder cancer	6.78e-05	0.00109	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—NAT1—urinary bladder cancer	6.78e-05	0.00109	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—TP53—urinary bladder cancer	6.74e-05	0.00108	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	6.71e-05	0.00108	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.67e-05	0.00107	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—SLC19A1—urinary bladder cancer	6.64e-05	0.00107	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PRSS3—urinary bladder cancer	6.47e-05	0.00104	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—HRAS—urinary bladder cancer	6.45e-05	0.00104	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—SLC19A1—urinary bladder cancer	6.3e-05	0.00101	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—TP53—urinary bladder cancer	6.27e-05	0.00101	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—UGT2B7—urinary bladder cancer	6.2e-05	0.000996	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PRSS3—urinary bladder cancer	6.14e-05	0.000986	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	6.11e-05	0.000981	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	5.93e-05	0.000952	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HDAC4—urinary bladder cancer	5.85e-05	0.00094	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	5.8e-05	0.000931	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GSTZ1—urinary bladder cancer	5.79e-05	0.00093	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	5.69e-05	0.000914	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—TNF—urinary bladder cancer	5.65e-05	0.000907	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	5.58e-05	0.000897	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	5.52e-05	0.000887	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NAT1—urinary bladder cancer	5.49e-05	0.000881	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GSTO2—urinary bladder cancer	5.49e-05	0.000881	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	5.4e-05	0.000867	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	5.27e-05	0.000847	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.19e-05	0.000834	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—TYMP—urinary bladder cancer	5.17e-05	0.000831	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PRSS3—urinary bladder cancer	5.14e-05	0.000825	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	5.03e-05	0.000807	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—UGT2B7—urinary bladder cancer	5.02e-05	0.000806	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.97e-05	0.000798	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	4.87e-05	0.000782	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	4.86e-05	0.000781	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	4.85e-05	0.000779	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	4.83e-05	0.000776	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—NAT2—urinary bladder cancer	4.68e-05	0.000752	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.66e-05	0.000749	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—LIG1—urinary bladder cancer	4.65e-05	0.000747	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	4.63e-05	0.000743	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CYP4B1—urinary bladder cancer	4.52e-05	0.000726	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	4.5e-05	0.000723	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	4.42e-05	0.000711	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IFNA2—urinary bladder cancer	4.31e-05	0.000692	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—SLC19A1—urinary bladder cancer	4.27e-05	0.000685	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PRSS3—urinary bladder cancer	4.16e-05	0.000668	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.12e-05	0.000662	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—TYMP—urinary bladder cancer	4.11e-05	0.00066	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—RRM2—urinary bladder cancer	4.04e-05	0.000649	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	4.03e-05	0.000648	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.95e-05	0.000634	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.94e-05	0.000633	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.76e-05	0.000603	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—HPGDS—urinary bladder cancer	3.74e-05	0.000601	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ENO2—urinary bladder cancer	3.74e-05	0.000601	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.72e-05	0.000598	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.72e-05	0.000597	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—NAT2—urinary bladder cancer	3.72e-05	0.000597	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	3.71e-05	0.000596	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GSTT1—urinary bladder cancer	3.63e-05	0.000583	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.57e-05	0.000574	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—ENO2—urinary bladder cancer	3.55e-05	0.00057	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—RBX1—urinary bladder cancer	3.36e-05	0.00054	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.33e-05	0.000535	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—TYMP—urinary bladder cancer	3.32e-05	0.000534	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.31e-05	0.000532	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	3.24e-05	0.00052	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—RRM2—urinary bladder cancer	3.21e-05	0.000515	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.19e-05	0.000513	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PLAU—urinary bladder cancer	3.06e-05	0.000491	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—NQO1—urinary bladder cancer	3.02e-05	0.000484	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—JAG1—urinary bladder cancer	3.01e-05	0.000483	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NAT2—urinary bladder cancer	3.01e-05	0.000483	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—HPGDS—urinary bladder cancer	2.97e-05	0.000477	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ENO2—urinary bladder cancer	2.97e-05	0.000477	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.95e-05	0.000474	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.93e-05	0.00047	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GSTT1—urinary bladder cancer	2.88e-05	0.000463	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.84e-05	0.000456	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—RRM2—urinary bladder cancer	2.59e-05	0.000417	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.55e-05	0.00041	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—CREBBP—urinary bladder cancer	2.52e-05	0.000405	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GSTP1—urinary bladder cancer	2.52e-05	0.000404	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IGF1—urinary bladder cancer	2.49e-05	0.0004	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.43e-05	0.000391	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ENO2—urinary bladder cancer	2.4e-05	0.000386	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—HPGDS—urinary bladder cancer	2.4e-05	0.000386	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—NQO1—urinary bladder cancer	2.39e-05	0.000385	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.39e-05	0.000384	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—TYMS—urinary bladder cancer	2.34e-05	0.000376	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GSTT1—urinary bladder cancer	2.33e-05	0.000374	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GSTM1—urinary bladder cancer	2.31e-05	0.000371	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—NCOR1—urinary bladder cancer	2.31e-05	0.000371	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.29e-05	0.000369	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—RHOA—urinary bladder cancer	2.28e-05	0.000366	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GPX1—urinary bladder cancer	2.21e-05	0.000356	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NCOR1—urinary bladder cancer	2.19e-05	0.000352	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.18e-05	0.000351	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ERCC2—urinary bladder cancer	2.17e-05	0.000349	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—ERCC2—urinary bladder cancer	2.06e-05	0.000331	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—MTHFR—urinary bladder cancer	2.04e-05	0.000328	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.03e-05	0.000325	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GSTP1—urinary bladder cancer	2e-05	0.000321	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NQO1—urinary bladder cancer	1.94e-05	0.000311	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MTHFR—urinary bladder cancer	1.94e-05	0.000311	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.93e-05	0.00031	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—TERT—urinary bladder cancer	1.93e-05	0.00031	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IL2—urinary bladder cancer	1.91e-05	0.000307	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.88e-05	0.000302	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—TYMS—urinary bladder cancer	1.86e-05	0.000298	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GSTM1—urinary bladder cancer	1.83e-05	0.000295	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—NCOR1—urinary bladder cancer	1.83e-05	0.000295	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—FGFR3—urinary bladder cancer	1.77e-05	0.000285	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GPX1—urinary bladder cancer	1.76e-05	0.000282	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ERCC2—urinary bladder cancer	1.73e-05	0.000277	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—EP300—urinary bladder cancer	1.72e-05	0.000276	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—SRC—urinary bladder cancer	1.67e-05	0.000268	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PPARG—urinary bladder cancer	1.66e-05	0.000266	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.64e-05	0.000263	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—MTHFR—urinary bladder cancer	1.62e-05	0.000261	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GSTP1—urinary bladder cancer	1.62e-05	0.00026	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CREBBP—urinary bladder cancer	1.59e-05	0.000256	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.56e-05	0.000251	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CREBBP—urinary bladder cancer	1.51e-05	0.000242	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—TYMS—urinary bladder cancer	1.5e-05	0.000241	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NCOR1—urinary bladder cancer	1.48e-05	0.000238	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GSTM1—urinary bladder cancer	1.48e-05	0.000238	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GPX1—urinary bladder cancer	1.42e-05	0.000228	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ERCC2—urinary bladder cancer	1.4e-05	0.000224	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—KRAS—urinary bladder cancer	1.38e-05	0.000222	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—RHOA—urinary bladder cancer	1.36e-05	0.000219	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PPARG—urinary bladder cancer	1.31e-05	0.000211	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—MTHFR—urinary bladder cancer	1.31e-05	0.000211	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PTGS2—urinary bladder cancer	1.3e-05	0.000209	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CREBBP—urinary bladder cancer	1.26e-05	0.000203	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—ERBB2—urinary bladder cancer	1.26e-05	0.000203	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—TP53—urinary bladder cancer	1.23e-05	0.000197	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—HRAS—urinary bladder cancer	1.17e-05	0.000189	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PTEN—urinary bladder cancer	1.14e-05	0.000183	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—EP300—urinary bladder cancer	1.08e-05	0.000174	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CDKN1A—urinary bladder cancer	1.08e-05	0.000173	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PTEN—urinary bladder cancer	1.08e-05	0.000173	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PPARG—urinary bladder cancer	1.06e-05	0.000171	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—EP300—urinary bladder cancer	1.03e-05	0.000165	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CREBBP—urinary bladder cancer	1.02e-05	0.000164	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—SRC—urinary bladder cancer	9.99e-06	0.00016	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PTEN—urinary bladder cancer	9.02e-06	0.000145	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MYC—urinary bladder cancer	8.95e-06	0.000144	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—EGFR—urinary bladder cancer	8.76e-06	0.000141	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—EP300—urinary bladder cancer	8.6e-06	0.000138	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PTGS2—urinary bladder cancer	8.37e-06	0.000134	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—KRAS—urinary bladder cancer	8.27e-06	0.000133	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PTEN—urinary bladder cancer	7.3e-06	0.000117	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HRAS—urinary bladder cancer	7.03e-06	0.000113	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—EP300—urinary bladder cancer	6.96e-06	0.000112	CbGpPWpGaD
